Evotec AG (NASDAQ:EVO) Given Consensus Rating of “Hold” by Brokerages

Shares of Evotec AG (NASDAQ:EVO) have been given an average recommendation of “Hold” by the four brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $3.00.

EVO has been the topic of a number of recent research reports. TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. HC Wainwright decreased their price target on shares of Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, July 15th. Weiss Ratings lowered shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. Finally, Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th.

Evotec Stock Performance

EVO opened at $1.82 on Wednesday. The business’s 50-day moving average price is $2.11 and its two-hundred day moving average price is $2.60. Evotec has a 1 year low of $1.80 and a 1 year high of $4.27. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Hedge Funds Weigh In On Evotec

Several hedge funds have recently modified their holdings of EVO. Apollon Wealth Management LLC acquired a new position in Evotec during the first quarter valued at approximately $28,000. Marshall Wace LLP acquired a new stake in shares of Evotec in the 4th quarter valued at approximately $40,000. SmartHarvest Portfolios LLC bought a new position in shares of Evotec in the first quarter valued at $44,000. BNP Paribas Financial Markets grew its stake in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the last quarter. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.